Blatt, K., Menzl, I., Eisenwort, G., Cerny-Reiterer, S., Herrmann, H., Herndlhofer, S., Stefanzl, G., Sadovnik, I., Berger, D., Keller, A., Hauswirth, A., Hoermann, G., Willmann, M., Rülicke, T., Sill, H., Sperr, W.R., Mannhalter, C., Melo, J.V., Jager, U., Sexl, V. and Valent, P. (2018) Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor Cells in Acute Lymphoblastic Leukemia. Neoplasia, 20, 632-642.
https://doi.org/10.1016/j.neo.2018.04.004

has been cited by the following article:

• TITLE: Angiogenic and FLT3 Receptors Expression in Acute Lymphoblastic Leukemia in Pediatric Age Group

  AUTHORS: Mona Hilmy Alrayes, Reham Hammad, Mohamed Abd Alazim Hussein EL Baddiny, Maha Saleh Madbouly Ibrahim, Mahmoud Hammad

  KEYWORDS: Childhood Leukemia, Angiogenesis, Vascular Endothelial Growth Factor Receptors, FLT3, Acute Lymphoblastic Leukemia

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.6, June 24, 2019

  ABSTRACT: Angiogenesis has an important role in pathophysiology of cancer. FMS-like tyrosine kinase 3 (FLT3) is implicated in hematopoietic malignancies. Their role in childhood acute lymphoblastic leukemia (ALL) pathogenesis needs more enlightenment. Expression of vascular endothelial growth factor receptor-1 and -2 (VEGFR-1 and -2), as well as FLT3 were assessed by flow cytometry in bone marrow (BM) blasts of 55 newly diagnosed children with ALL. Patients included B cell ALL (B-ALL) group (n = 41) and T cell ALL (T-ALL) group (n = 14). Comparison between groups revealed a significant increase in blasts percent (%) expressing FLT3 and FLT3 intensity detected in B-ALL group (p = 0.004 and p = 0.02, respectively). In B-ALL patients, a significant positive correlation was seen between blasts % expressing FLT3 and blasts percentage infiltrating BM (r = 0.405; p = 0.009), also positive correlation was seen between % of blasts expressing VEGFR-1 and VEGFR-2 (r = 0.704; p 0.001). In T-ALL group, blast % expressing FLT3 revealed significant positive correlations with blast % expressing VEGFR-1, and those expressing VEGFR-2 (r = 0.627; p = 0.016, and r = 0.654; p = 0.011, respectively). In addition, significant correlation was seen in blasts % expressing all; FLT3, VEGFR-1 and -2, with blasts % expressing stem cell marker CD34 (r = 0.826; p = 0.001, r = 0.596; p = 0.041, and r = 0.798; p = 0.002, respectively). Conclusion: Expression of VEGFR-1, VEGFR-2 and FLT3 were demonstrated and linked on leukemic blasts of ALL which highlights their role in pathogenesis. FLT3 expression plays a role in facilitating blasts proliferation in BM in B-ALL. FLT3, VEGFR-1 and -2 could be used in future profiling of CD34+ leukemic stem cell pool in T-ALL.